DataMEDS AI Stock Surges Wednesday: What's Driving the Action?
DataMEDS AI is surging Wednesday as investors digest the acquisition of an AI cancer diagnostics lab and contract research businesses.
Stocks · News reference
Axe Compute Announces Sale Of Helomics Cancer Diagnostics Unit To DataMEDS AI For Common Shares And Share Equivalents; Share Count Not Disclosed
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
DataMEDS AI Stock Soars 65% Pre-market: Here's What You Need to Know
DataMEDS AI shares jumped 8.02% in overnight session Tuesday after the company completed its $1.5 million Helomics acquisition.